<DOC>
	<DOCNO>NCT00553345</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming . The use selenium vitamin E may stop cancer grow come back . PURPOSE : This randomized phase III trial study give selenium together vitamin E see well work compare placebo prevent cancer progression recurrence patient early-stage bladder cancer .</brief_summary>
	<brief_title>Selenium Vitamin E Preventing Cancer Progression Recurrence Patients With Early-Stage Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To investigate whether selenium and/or vitamin E ( α-tocopherol ) supplementation reduces risk recurrence progression . OUTLINE : This multicenter study . Patients stratify recurrence risk group ( high v intermediate ) treatment center randomize 1 4 treatment arm . - Arm I : Patients receive oral selenium tablet oral vitamin E capsule daily . - Arm II : Patients receive oral selenium tablet oral placebo capsule daily . - Arm III : Patients receive oral placebo tablet oral vitamin E capsule daily . - Arm IV : Patients receive oral placebo tablet oral placebo capsule daily . In arm , treatment continue 5 year absence disease progression unacceptable toxicity . Quality life assess every 6 month 5 year . Peer Reviewed Funded Endorsed Cancer Research UK .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histopathologically confirm nonmuscleinvasive transitional cell carcinoma ( &lt; pT2 ) Newly diagnose disease Able randomize within twelve month diagnostic transurethral resection bladder tumor/biopsy Must meet 1 follow recurrence risk criterion : Intermediate risk Multiple G1 pTa ( &gt; 1 ) Solitary G1 pTa ( ≥ 3 cm ) G2 pTa G1 pT1 G2 pT1 ( 1 2 tumor ) High risk G3 pTa G3 pT1 Cis Multiple G2 pT1 ( 3 focus ) Low risk Solitary G1 pTa &lt; 3 cm PATIENT CHARACTERISTICS : Not pregnant breast feed No HIV infection No condition , opinion local investigator , might interfere safety patient evaluation trial objective PRIOR CONCURRENT THERAPY : No concurrent immunosuppressive therapy organ transplantation No concurrent cyclosporine Those currently use used selenium and/or vitamin E supplement exclude , however , must agree take supplement contain selenium vitamin E prespecified dosage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
</DOC>